Tags

Type your tag names separated by a space and hit enter

Nabilone for the treatment of pain in fibromyalgia.
J Pain. 2008 Feb; 9(2):164-73.JP

Abstract

A randomized, double-blind, placebo-controlled trial was conducted to determine the benefit of nabilone in pain management and quality of life improvement in 40 patients with fibromyalgia. After a baseline assessment, subjects were titrated up on nabilone, from 0.5 mg PO at bedtime to 1 mg BID over 4 weeks or received a corresponding placebo. At the 2- and 4-week visits, the primary outcome measure, visual analog scale (VAS) for pain, and the secondary outcome measures, number of tender points, the average tender point pain threshold, and the Fibromyalgia Impact Questionnaire (FIQ), were evaluated. After a 4-week washout period, subjects returned for reassessment of the outcome measures. There were no significant differences in population demographics between groups at baseline. There were significant decreases in the VAS (-2.04, P < .02), FIQ (-12.07, P < .02), and anxiety (-1.67, P < .02) in the nabilone treated group at 4 weeks. There were no significant improvements in the placebo group. The treatment group experienced more side effects per person at 2 and 4 weeks (1.58, P < .02 and 1.54, P < .05), respectively. Nabilone appears to be a beneficial, well-tolerated treatment option for fibromyalgia patients, with significant benefits in pain relief and functional improvement.

PERSPECTIVE

To our knowledge, this is the first randomized, controlled trial to assess the benefit of nabilone, a synthetic cannabinoid, on pain reduction and quality of life improvement in patients with fibromyalgia. As nabilone improved symptoms and was well-tolerated, it may be a useful adjunct for pain management in fibromyalgia.

Authors+Show Affiliations

Section of Physical Medicine and Rehabilitation, University of Manitoba, Rehabilitation Hospital, Health Sciences Centre, Winnipeg, Manitoba, Canada. rskrabek@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17974490

Citation

Skrabek, Ryan Quinlan, et al. "Nabilone for the Treatment of Pain in Fibromyalgia." The Journal of Pain : Official Journal of the American Pain Society, vol. 9, no. 2, 2008, pp. 164-73.
Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164-73.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. The Journal of Pain : Official Journal of the American Pain Society, 9(2), 164-73.
Skrabek RQ, et al. Nabilone for the Treatment of Pain in Fibromyalgia. J Pain. 2008;9(2):164-73. PubMed PMID: 17974490.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nabilone for the treatment of pain in fibromyalgia. AU - Skrabek,Ryan Quinlan, AU - Galimova,Lena, AU - Ethans,Karen, AU - Perry,Daryl, Y1 - 2007/11/05/ PY - 2007/04/19/received PY - 2007/08/27/revised PY - 2007/09/26/accepted PY - 2007/11/3/pubmed PY - 2008/3/19/medline PY - 2007/11/3/entrez SP - 164 EP - 73 JF - The journal of pain : official journal of the American Pain Society JO - J Pain VL - 9 IS - 2 N2 - UNLABELLED: A randomized, double-blind, placebo-controlled trial was conducted to determine the benefit of nabilone in pain management and quality of life improvement in 40 patients with fibromyalgia. After a baseline assessment, subjects were titrated up on nabilone, from 0.5 mg PO at bedtime to 1 mg BID over 4 weeks or received a corresponding placebo. At the 2- and 4-week visits, the primary outcome measure, visual analog scale (VAS) for pain, and the secondary outcome measures, number of tender points, the average tender point pain threshold, and the Fibromyalgia Impact Questionnaire (FIQ), were evaluated. After a 4-week washout period, subjects returned for reassessment of the outcome measures. There were no significant differences in population demographics between groups at baseline. There were significant decreases in the VAS (-2.04, P < .02), FIQ (-12.07, P < .02), and anxiety (-1.67, P < .02) in the nabilone treated group at 4 weeks. There were no significant improvements in the placebo group. The treatment group experienced more side effects per person at 2 and 4 weeks (1.58, P < .02 and 1.54, P < .05), respectively. Nabilone appears to be a beneficial, well-tolerated treatment option for fibromyalgia patients, with significant benefits in pain relief and functional improvement. PERSPECTIVE: To our knowledge, this is the first randomized, controlled trial to assess the benefit of nabilone, a synthetic cannabinoid, on pain reduction and quality of life improvement in patients with fibromyalgia. As nabilone improved symptoms and was well-tolerated, it may be a useful adjunct for pain management in fibromyalgia. SN - 1526-5900 UR - https://www.unboundmedicine.com/medline/citation/17974490/Nabilone_for_the_treatment_of_pain_in_fibromyalgia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1526-5900(07)00873-5 DB - PRIME DP - Unbound Medicine ER -